Bendamustine Plus Rituximab as Salvage Treatment for Patients with Relapsed or Refractory Low-grade B-cell Lymphoma and Mantle Cell Lymphoma: A Single-Center Retrospective Study
| Autor: | Murakami, Hiroyuki, Yoshioka, Takanori, Moriyama, Takashi, Ishikawa, Tatsunori, Makita, Masanori, Sunami, Kazutaka |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Adult
Aged 80 and over Male Salvage Therapy Lymphoma B-Cell mantle cell lymphoma Lymphoma Mantle-Cell Middle Aged Disease-Free Survival Progression-Free Survival Antineoplastic Agents Immunological Japan hemic and lymphatic diseases Antineoplastic Combined Chemotherapy Protocols Bendamustine Hydrochloride Humans Female bendamustine Neoplasm Recurrence Local Rituximab Antineoplastic Agents Alkylating low grade B-cell lymphoma Aged Retrospective Studies |
| Zdroj: | Acta medica Okayama. 75(4) |
| ISSN: | 0386-300X |
| Popis: | Bendamustine plus rituximab (B-R) is an effective therapy for relapsed or refractory (r/r) low-grade B-cell lymphoma (LGBCL) and mantle cell lymphoma (MCL); however, clinical data from Japanese patients treated with B-R therapy are limited. We retrospectively evaluated the efficacy and safety of B-R therapy in 42 patients who received B-R therapy at our hospital for r/r LGBCL and MCL. All patients received intravenous (IV) ritux-imab 375 mg/m2 on day 1 and IV bendamustine 90 mg/m2 on days 2 and 3 every 28 days for up to 6 cycles. The common histologic subtypes were follicular lymphoma (n = 29, 70%), marginal zone lymphoma (n = 6, 14%), and MCL (n = 5, 12%). The overall response rate was 93%, with 62% complete response and complete response unconfirmed. The median progression-free survival (PFS) was 38 months (95% confidence interval [CI], 24.6 to not reached [NR]), and the median overall survival (OS) was 80 months (95% CI, 60.7 to NR). Patients receiving a cumulative dose of bendamustine ≥ 720 mg/m2 showed a significantly longer PFS and OS. Grade 3/4 adverse events (≥ 10%) included neutropenia (55%), lymphopenia (69%), and nausea (24%). B-R therapy was effective and well tolerated, and the cumulative dose of bendamustine was associated with a favorable outcome. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|